Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction

New England Journal of Medicine

Volumn 354, Issue 14, 2006, Pages 1477-1488

  Antman, Elliott M ^a   Morrow, David A ^a   McCabe, Carolyn H ^a   Murphy, Sabina A ^a   Ruda, Mikhail ^b   Sadowski, Zygmunt ^c   Budaj, Andrzej ^d   López Sendón, Jose L ^e   Guneri, Sema ^f   Jiang, Frank ^g   White, Harvey D ^h   Fox, Keith A A ⁱ   Braunwald, Eugene ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b INSTITUTE OF EXPERIMENTAL CARDIOLOGY   (Russian Federation)

^c INSTITUTE OF CARDIOLOGY   (Poland)

^d GROCHOWSKI HOSPITAL   (Poland)

^e HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^f DOKUZ EYLUL UNIVERSITY   (Turkey)

^g SANOFI   (France)

^h AUCKLAND CITY HOSPITAL   (New Zealand)

ⁱ UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ENOXAPARIN; HEPARIN; PLACEBO;

ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG SAFETY; FEMALE; FIBRINOLYSIS; HEART DEATH; HEART INFARCTION; HEART REINFARCTION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVASCULARIZATION; ST SEGMENT ELEVATION;

AGED; ANTICOAGULANTS; DRUG THERAPY, COMBINATION; ELECTROCARDIOGRAPHY; ENOXAPARIN; FEMALE; FIBRINOLYTIC AGENTS; HEMORRHAGE; HEPARIN; HUMANS; INTRACRANIAL HEMORRHAGES; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RECURRENCE; RISK; TREATMENT OUTCOME;

EID: 33645515458     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa060898     Document Type: Article

References (24)

1. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Bethesda, Md.: American College of Cardiology Foundation, 2004. (Accessed March 13, 2006, at http://www.acc.org/ clinical/guidelines/stemi/index.pdf.)
2. Van de Werf F, Ardissino D, Betriu A, et al. Management of acute myocardial infarction in patients presenting with STsegment elevation. Eur Heart J 2003;24:28-66.
3. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet 1990;336:65-71.
4. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 1992;339:753-70.
5. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673-82.
6. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 1996;335:775-82.
7. Antman EM. Hirudin in acute myocardial infarction: Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial. Circulation 1996;94:911-21.
8. The Continuous Infusion versus Double-Bolus Administration of Alteplase (COBALT) Investigators. A comparison of continuous infusion of alteplase with double-bolus administration for acute myocardial infarction. N Engl J Med 1997;337:1124-30.
9. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators. A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med 1997;337:1118-23.
10. Antman EM. The search for replacements for unfractionated heparin. Circulation 2001;103:2310-4.
11. Antman EM, Morrow DA, McCabe CH, et al. Enoxaparin versus unfractionated heparin as antithrombin therapy in patients receiving fibrinolysis for ST-elevation myocardial infarction: design and rationale for the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25). Am Heart J 2005;149:217-26.
12. Eikelboom JW, Quinlan DJ, Mehta SR, Turpie AG, Menown IB, Yusuf S. Unfractionated and low-molecular-weight heparin as adjuncts to thrombolysis in aspirintreated patients with ST-elevation acute myocardial infarction: a meta-analysis of the randomized trials. Circulation 2005;112:3855-67.
13. Wallentin L, Goldstein P, Armstrong PW, et al. Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction. Circulation 2003;108:135-42.
14. Topol EJ, George BS, Kereiakes DJ, et al. A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction. Circulation 1989;79:281-6.
15. Hsia J, Hamilton WP, Kleiman N, Roberts R, Chaitman BR, Ross AM. A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 1990;323:1433-7.
16. de Bono DP, Simoons ML, Tijssen J, et al. Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomised double blind European Cooperative Study Group trial. Br Heart J 1992;67:122-8.
17. Mueller HS, Forman SA, Menegus MA, Cohen LS, Knatterud GL, Braunwald E. Prognostic significance of nonfatal reinfarction during 3-year follow-up: results of the Thrombolysis in Myocardial Infarction (TIMI) phase II clinical trial. J Am Coll Cardiol 1995;26:900-7.
18. Ohman EM, Califf RM, Topol EJ, et al. Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. Circulation 1990;82:781-91.
19. Gibson CM, Karha J, Murphy SA, et al. Early and long-term clinical outcomes associated with reinfarction following fibrinolytic administration in the Thrombolysis in Myocardial Infarction trials. J Am Coll Cardiol 2003;42:7-16.
20. Gash AK, Spann JF, Sherry S, et al. Factors influencing reocclusion after coronary thrombolysis for acute myocardial infarction. Am J Cardiol 1986;57:175-7.
21. Gulba DC, Barthels M, Westhoff-Bleck M, et al. Increased thrombin levels during thrombolytic therapy in acute myocardial infarction: relevance for the success of therapy. Circulation 1991;83:937-44.
22. Harrison DG, Ferguson DW, Collins SM, et al. Rethrombosis after reperfusion with streptokinase: importance of geometry of residual lesions. Circulation 1984;69:991-9.
23. Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997;337:688-98. [Erratum, N Engl J Med 1997;337:1567.]
24. Thompson PL, Aylward PE, Federman J, et al. A randomized comparison of intravenous heparin with oral aspirin and dipyridamole 24 hours after recombinant tissue-type plasminogen activator for acute myocardial infarction. Circulation 1991;83:1534-42.